BC Extra | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
BC Week In Review | Sep 21, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...
BC Extra | Sep 20, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...
BC Week In Review | Oct 5, 2015
Financial News

Mirna Therapeutics completes IPO

Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas   Business: Cancer   Date completed: 2015-10-01   Type: IPO   Raised: $43.8 million   Shares: 6.3 million   Price: $7   Shares after offering: 20.1 million   Underwriters:...
BC Week In Review | Oct 5, 2015
Financial News

Mirna Therapeutics completes private placement

Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas   Business: Cancer   Date completed: 2015-10-01   Type: Private placement   Raised: $16.8 million   Shares: 2.4 million   Price: $7   Shares after offering: 20.1 million  ...
BC Week In Review | Sep 28, 2015
Company News

immatics, University of Texas MD Anderson Cancer Center cancer news

immatics and MD Anderson launched standalone company Immatics US Inc. (Houston, Texas) to develop autologous and allogeneic adoptive cellular therapies to treat tumors. The newco has access to MD Anderson’s expertise and immatics’ “cancer target...
BC Week In Review | Sep 28, 2015
Financial News

Mirna amends IPO

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date announced: 2015-09-18   Type: IPO   To be raised: Up to $69.8 million   Shares: 4.7 million   Price: $13-$15   Underwriters: Citigroup; Leerink Partners;...
BC Week In Review | Sep 14, 2015
Financial News

Mirna amends IPO

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date announced: 2015-09-11   Type: IPO   To be raised: Up to $80.5 million   Shares: TBD   Price: TBD   Underwriters: Citigroup; Leerink Partners; Oppenheimer;...
BC Innovations | Feb 5, 2015
Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
BC Innovations | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
Items per page:
1 - 10 of 29
BC Extra | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
BC Week In Review | Sep 21, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...
BC Extra | Sep 20, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...
BC Week In Review | Oct 5, 2015
Financial News

Mirna Therapeutics completes IPO

Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas   Business: Cancer   Date completed: 2015-10-01   Type: IPO   Raised: $43.8 million   Shares: 6.3 million   Price: $7   Shares after offering: 20.1 million   Underwriters:...
BC Week In Review | Oct 5, 2015
Financial News

Mirna Therapeutics completes private placement

Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas   Business: Cancer   Date completed: 2015-10-01   Type: Private placement   Raised: $16.8 million   Shares: 2.4 million   Price: $7   Shares after offering: 20.1 million  ...
BC Week In Review | Sep 28, 2015
Company News

immatics, University of Texas MD Anderson Cancer Center cancer news

immatics and MD Anderson launched standalone company Immatics US Inc. (Houston, Texas) to develop autologous and allogeneic adoptive cellular therapies to treat tumors. The newco has access to MD Anderson’s expertise and immatics’ “cancer target...
BC Week In Review | Sep 28, 2015
Financial News

Mirna amends IPO

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date announced: 2015-09-18   Type: IPO   To be raised: Up to $69.8 million   Shares: 4.7 million   Price: $13-$15   Underwriters: Citigroup; Leerink Partners;...
BC Week In Review | Sep 14, 2015
Financial News

Mirna amends IPO

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date announced: 2015-09-11   Type: IPO   To be raised: Up to $80.5 million   Shares: TBD   Price: TBD   Underwriters: Citigroup; Leerink Partners; Oppenheimer;...
BC Innovations | Feb 5, 2015
Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
BC Innovations | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
Items per page:
1 - 10 of 29